arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

SUPERNUS PHARMACEUTICALS, INC.

SUPN
$26.77 ▼ -1.50 (-5.32%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

SUPERNUS PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.6B
Dividend Yield —
Revenue Growth 18.0% ↘
Op. Margin 9.3% ↗
ROIC 1.8% ↗
FCF / Share $0.11 ↗
Trailing P/E 74.4x
Price / Book 1.5x
FCF Yield 0.4%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$226.77M
↑ +18.0% —
Net Income Profit after all expenses
$-2.29M
↑ +80.6% —
Operating Margin Operating profit as % of sales
9.3%
↑ +135.3% 16th
FCF / Share Free cash flow per share
$0.11
↑ +218.3% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
29
Returns
40
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 16 years · 62 quarters